| Budget Amount *help |
¥45,110,000 (Direct Cost: ¥34,700,000、Indirect Cost: ¥10,410,000)
Fiscal Year 2023: ¥8,840,000 (Direct Cost: ¥6,800,000、Indirect Cost: ¥2,040,000)
Fiscal Year 2022: ¥8,840,000 (Direct Cost: ¥6,800,000、Indirect Cost: ¥2,040,000)
Fiscal Year 2021: ¥8,840,000 (Direct Cost: ¥6,800,000、Indirect Cost: ¥2,040,000)
Fiscal Year 2020: ¥8,840,000 (Direct Cost: ¥6,800,000、Indirect Cost: ¥2,040,000)
Fiscal Year 2019: ¥9,750,000 (Direct Cost: ¥7,500,000、Indirect Cost: ¥2,250,000)
|
|---|
| Outline of Final Research Achievements |
In this research project, we analyzed the differentiation mechanism of inflammatory T helper (Th17) cells that produce the inflammatory cytokine interleukin-17, and the mechanism of inflammation aggravation due to interaction with other inflammation-related cells.
We identified the characteristics of Th17 cells that are highly pathogenic in the arthritic joints. We also revealed the mechanism by which interleukin-23-producing cells, which strongly regulate the function of Th17 cells, acquire functions in the gut. We elucidated that Gsdmd and Ripk3 are not involved as factors that exacerbate and aggravate inflammation, and on the other hand, we found the role of CCR2+ inflammatory monocytes that aggravate synovial inflammation.
|
